News 1+1丨Vaccines + specific drugs, can the new crown epidemic end?

　　"Vaccine + specific medicine" is a combination of epidemic prevention that has always been highly anticipated by everyone.

Up to now, my country's new crown vaccination has exceeded 2.4 billion doses; up to now, my country has independently developed 6 kinds of new crown specific drugs.

"News 1+1" invited Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, and Peking University professor Xie Xiaoliang, to pay attention to: vaccine + specific drugs, can the new crown epidemic end?

　　1

　　"One small and one old" among the vaccinated population

　　At present, more than 84 million people in my country between the ages of 3 and 11 have been vaccinated with the new crown vaccine, and 49.44 million people have been vaccinated for the booster immunization.

On the other hand, the vaccination rate of the elderly still needs to be greatly increased.

　　2

　　What is the difference between vaccinations in children and adolescents and adults?

　　Wang Huaqing: At present, children and adolescents are vaccinated. The composition and dosage of the vaccine are the same as those used by adults.

Children receive two doses of inactivated vaccine. In terms of the interval, the procedures and requirements are also the same, which is greater than or equal to more than 3 weeks. Try to complete the second vaccination within 8 weeks.

　　3

　　What are the adverse reactions of children's vaccination?

　　Wang Huaqing: To observe and understand the adverse reactions, we mainly refer to two results.

　　① Pre-vaccine clinical trials.

　　There was no significant difference in the incidence of adverse reactions between the children and adolescents in clinical trials and the adult group.

　　②The test results that have been inoculated.

　　Children and adolescents have been vaccinated more frequently. According to the results of our current monitoring, the overall incidence of vaccine adverse reactions is not higher than that of adults.

Of course, in the later stage, we must further monitor and analyze the suspected adverse reactions of the new crown vaccine to ensure the smooth progress of the new crown vaccination.

　　4

　　In the development of specific drugs, "difficult to do clinical trials" becomes a problem

　　Xie Xiaoliang: Due to China's effective control of the epidemic, there are very few domestic patients and it is difficult to conduct clinical trials. It must be done abroad, which is very difficult.

　　Of course there are other problems, one of which is the virus variant.

Our first antibody completed the Phase II clinical trial abroad, and the results were good, but the mutant strain came, and the first antibody was escaped as a result, that is, completely invalidated. All our investment was wasted. Our second antibody, DXP-604, survived.

　　Therefore, I think the most difficult thing is to prevent the antibody from being escaped by the virus.